After several weeks of visiting various websites for pharmaceutical companies and their front organizations, I’ve gotten a little tired of reading the same old, same old over and over again. To recap for those of you joining late, I’ve been out on the cyberhighway visiting Big Pharma’s and their trade groups’ websites looking for any sign of their being aware of the impending financial disaster about to overtake them. Needless to say, I haven’t found much.
I’ve always thought that I was reasonably knowledgeable about what goes down in the life sciences industry. But, I’ve been shocked by the sameness of the various sites that I’ve been visiting and the total lack of any sense of awareness of the industry’s impending problems.
I spent some time with Larry this week going over the results to date. We feel that we’ve done sufficient research so far and don’t think that blogging about additional site visits are going to add much at this time and we don’t want to run the risk of boring our readers. So, we’re going to change our approach a bit. We’d been planning this anyway but we’re going to speed things up a bit. (But, if any of you out there are aware of any pharmaceutical sites that we should visit, please send them in.)
Starting this week, we’re going to start looking for the analysts and other industry pundits are saying. We also want to go back and do something that we haven’t done for a while – live interviews with some people whom we’ve met with before.
This week while doing my research, I came across Derek Lowe’s Seeking Alpha website (http://seekingalpha.com ) and an article that he wrote titled Big Pharma’s Future Death Spiral (http://seekingalpha.com/article/162227-big-pharma-s-future-death-spiral ). The author summarizes and comments on a presentation called The Pharma Titanic: It's Time to Root for the Iceberg given by Stefan Loren of Westwicke Partners, a Baltimore based financial firm. (What’s with all these Titanic analogies?) Stefan does a very good job of hitting on the major issues confronting Big Pharma. In particular, he not only discusses the vanishing product pipeline issue but goes into how poorly new product research and development have been managed. Derek’s comments are also very good. I recommend visiting the site and reading the article.
I came across another interesting link to Stefan’s work (http://www.chemoutsourcing.com/ChemOutsourcing08final.pdf ). The link shows a Powerpoint presentation entitled Is the Pharmaceutical Industry Exposing Itself to Unacceptable Risk by Expanding Offshore Outsourcing? The presentation is a very good summary of current trends and future outcomes. And, while not all gloom and doom, Stefan hints at a very different future.
I’m encouraged by articles like these because some people connected with the industry don’t have their heads in the sand. (Although, they generally don’t work for pharmaceutical companies.) We’ll continue to seek out these folks and hope to visit with some of them in the future.
As always, we welcome your feedback. Please contact us at larryrothmansblog@gmail.com. We look forward to hearing from you.
Contributed by Guy de Lastin
The Pharmaceutical/Life Sciences Industries are undergoing a profound change. As the business goes more towards a bottom line management focus, savings from consulting, outsourcing (globalization) and outside technical services become more important. This Blog is focused on serving the interests of those industry clients, investors and their suppliers. We will discuss issues related to the politics, finance and technology and their impact on the industry.
Showing posts with label Titanic. Show all posts
Showing posts with label Titanic. Show all posts
Sunday, October 3, 2010
Sunday, September 26, 2010
The Journey Continues – Down the Rabbit Hole
After several weeks of visiting Big Pharma’s websites or those of their agents, I’m still shaking my head over what I’ve been finding. Namely, nothing. Last week I used the overused analogy about the Titanic. This week, I followed the Avandia story and thought maybe I would finally find a company that I might be on the cusp of finding a company, GlaxoSmithKline (GSK) in this case, finally having to recognize reality. Well, with apologies to Lewis Carroll, I was wrong and went down the rabbit hole.
First, a quick recap. This past week, the FDA placed serious restrictions on GSK’s diabetes drug, Avandia, while, the EMA instituted a recall. (Details can be found at the website Avandia Recall News (http://avandiarecallnews.com/ ).) So, in my innocence, I thought that maybe GSK’s website (http://www.gsk.com/index.htm ) might have some insight and reflection on what’s going on. As you’ve probably guessed by now, I got that one wrong.
At GSK’s website, I found contact information for patients, medical professionals, investors and the media. There was also a statement and video from Dr. Ellen Strahlman, GSK’s chief medical officer. (I wonder where their CEO, Andrew Witty, is in all this.) It had the air of being slapped together. In fairness, I guess that would be the first reaction. But, as I went over the website, I found what I’d found earlier at other Big Pharma websites and that was a complete lack of concern over where the industry is going.
GSK’s three strategic priorities (http://www.gsk.com/mission-strategy/index.htm ) are plastered all over their website. But, I find them to be the usual corporate fluff that doesn’t seem to be focused on the industry’s problems. The website is not as well laid out as some of their competitors and its message was confusing to me.
For me, my journey has, so far, not been very encouraging. This week’s visit is the capstone of this trip. Here’s a major drug company facing a global recall on one of its major products and it’s being treated like a minor appliance recall would be in another industry. Sure, I get the fact that for legal and regulatory reasons many things cannot be said. But, where’s the awareness that a very different regulatory climate is forming out there and this is even before U.S. healthcare reform kicks in. Where’s the leadership? Either at a company level or in the industry? I don’t see it.
I don’t mean to be an alarmist but I believe that we’re seeing another major industry preparing to roll over and go to the bottom. I’ll continue with this blog stream for a while longer because I want to learn if anyone in the industry is thinking about this.
As always, we welcome your feedback. Please contact us at larryrothmansblog@gmail.com. We look forward to hearing from you.
Contributed by Guy de Lastin
First, a quick recap. This past week, the FDA placed serious restrictions on GSK’s diabetes drug, Avandia, while, the EMA instituted a recall. (Details can be found at the website Avandia Recall News (http://avandiarecallnews.com/ ).) So, in my innocence, I thought that maybe GSK’s website (http://www.gsk.com/index.htm ) might have some insight and reflection on what’s going on. As you’ve probably guessed by now, I got that one wrong.
At GSK’s website, I found contact information for patients, medical professionals, investors and the media. There was also a statement and video from Dr. Ellen Strahlman, GSK’s chief medical officer. (I wonder where their CEO, Andrew Witty, is in all this.) It had the air of being slapped together. In fairness, I guess that would be the first reaction. But, as I went over the website, I found what I’d found earlier at other Big Pharma websites and that was a complete lack of concern over where the industry is going.
GSK’s three strategic priorities (http://www.gsk.com/mission-strategy/index.htm ) are plastered all over their website. But, I find them to be the usual corporate fluff that doesn’t seem to be focused on the industry’s problems. The website is not as well laid out as some of their competitors and its message was confusing to me.
For me, my journey has, so far, not been very encouraging. This week’s visit is the capstone of this trip. Here’s a major drug company facing a global recall on one of its major products and it’s being treated like a minor appliance recall would be in another industry. Sure, I get the fact that for legal and regulatory reasons many things cannot be said. But, where’s the awareness that a very different regulatory climate is forming out there and this is even before U.S. healthcare reform kicks in. Where’s the leadership? Either at a company level or in the industry? I don’t see it.
I don’t mean to be an alarmist but I believe that we’re seeing another major industry preparing to roll over and go to the bottom. I’ll continue with this blog stream for a while longer because I want to learn if anyone in the industry is thinking about this.
As always, we welcome your feedback. Please contact us at larryrothmansblog@gmail.com. We look forward to hearing from you.
Contributed by Guy de Lastin
Subscribe to:
Posts (Atom)